home / stock / eypt / eypt articles
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced interim masked safety data for its lead product candidate EYP-1901 from its ongoing Phas...
EW Healthcare Partners LP, 10% Owner at EyePoint Pharmaceuticals (NASDAQ:EYPT), reported a large insider sell on September 6, according to a new SE...
EW Healthcare Partners LP, 10% Owner at EyePoint Pharmaceuticals (NASDAQ:EYPT), reported a large insider sell on August 30, according to a new SEC ...
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developi...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...